Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119,804 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Why Target the Gut to Treat IgA Nephropathy?
Barratt J, Rovin BH, Cattran D, Floege J, Lafayette R, Tesar V, Trimarchi H, Zhang H; NefIgArd Study Steering Committee. Barratt J, et al. Among authors: zhang h. Kidney Int Rep. 2020 Aug 20;5(10):1620-1624. doi: 10.1016/j.ekir.2020.08.009. eCollection 2020 Oct. Kidney Int Rep. 2020. PMID: 33102954 Free PMC article. No abstract available.
Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool.
Barbour SJ, Canney M, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, Katafuchi R, Induruwage D, Er L, Reich HN, Feehally J, Barratt J, Cattran DC; International IgA Nephropathy Network. Barbour SJ, et al. Among authors: zhang h. Kidney Int. 2020 Oct;98(4):1009-1019. doi: 10.1016/j.kint.2020.04.042. Epub 2020 May 25. Kidney Int. 2020. PMID: 32464215
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Perkovic V, et al. Among authors: zhang h. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14. N Engl J Med. 2019. PMID: 30990260 Free article. Clinical Trial.
Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy.
Canney M, Barbour SJ, Zheng Y, Coppo R, Zhang H, Liu ZH, Matsuzaki K, Suzuki Y, Katafuchi R, Reich HN, Cattran D; International IgA Nephropathy Network; International IgA Nephropathy Network Investigators. Canney M, et al. Among authors: zhang h. J Am Soc Nephrol. 2021 Feb;32(2):436-447. doi: 10.1681/ASN.2020030349. Epub 2020 Dec 23. J Am Soc Nephrol. 2021. PMID: 33514642 Free PMC article.
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Barratt J, et al. Among authors: zhang h. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. Kidney Int. 2023. PMID: 36270561 Free article. Clinical Trial.
119,804 results
You have reached the last available page of results. Please see the User Guide for more information.